These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 34132050)
21. Novel nano-drug delivery system for natural products and their application. Huang L; Huang XH; Yang X; Hu JQ; Zhu YZ; Yan PY; Xie Y Pharmacol Res; 2024 Mar; 201():107100. PubMed ID: 38341055 [TBL] [Abstract][Full Text] [Related]
22. Effects of Dissolution Medium pH and Simulated Gastrointestinal Contraction on Drug Release From Nifedipine Extended-Release Tablets. Gao Z; Ngo C; Ye W; Rodriguez JD; Keire D; Sun D; Wen H; Jiang W J Pharm Sci; 2019 Mar; 108(3):1189-1194. PubMed ID: 30343136 [TBL] [Abstract][Full Text] [Related]
23. Physiologically Based In vitro Models to Predict the Oral Dissolution and Absorption of a Solid Drug Delivery System. Li Z; He X Curr Drug Metab; 2015; 16(9):777-806. PubMed ID: 26264200 [TBL] [Abstract][Full Text] [Related]
24. Can dosage form-dependent food effects be predicted using biorelevant dissolution tests? Case example extended release nifedipine. Andreas CJ; Tomaszewska I; Muenster U; van der Mey D; Mueck W; Dressman JB Eur J Pharm Biopharm; 2016 Aug; 105():193-202. PubMed ID: 27322002 [TBL] [Abstract][Full Text] [Related]
25. Prediction of the in vivo performance of enteric coated pellets in the fasted state under selected biorelevant dissolution conditions. Stefanič M; Vrečer F; Rizmal P; Mrhar A; Bogataj M Eur J Pharm Sci; 2014 Oct; 62():8-15. PubMed ID: 24844699 [TBL] [Abstract][Full Text] [Related]
26. Screening of Bioequivalent Extended-Release Formulations for Metformin by Principal Component Analysis and Convolution-Based IVIVC Approach. Zhang Y; Liu H; Tang MJ; Ho NJ; Shek TL; Yang Z; Zuo Z AAPS J; 2021 Mar; 23(2):38. PubMed ID: 33665728 [TBL] [Abstract][Full Text] [Related]
27. In vitro dissolution models for the prediction of in vivo performance of an oral mesoporous silica formulation. McCarthy CA; Faisal W; O'Shea JP; Murphy C; Ahern RJ; Ryan KB; Griffin BT; Crean AM J Control Release; 2017 Mar; 250():86-95. PubMed ID: 28132935 [TBL] [Abstract][Full Text] [Related]
28. Nano-based drug delivery system for therapeutics: a comprehensive review. Prakash S Biomed Phys Eng Express; 2023 Aug; 9(5):. PubMed ID: 37549657 [TBL] [Abstract][Full Text] [Related]
29. Critical quality attributes in the development of therapeutic nanomedicines toward clinical translation. Taha MS; Padmakumar S; Singh A; Amiji MM Drug Deliv Transl Res; 2020 Jun; 10(3):766-790. PubMed ID: 32170656 [TBL] [Abstract][Full Text] [Related]
30. In vitro/in vivo correlations of dissolution data of carbamazepine immediate release tablets with pharmacokinetic data obtained in healthy volunteers. Lake OA; Olling M; Barends DM Eur J Pharm Biopharm; 1999 Jul; 48(1):13-9. PubMed ID: 10477323 [TBL] [Abstract][Full Text] [Related]
31. Establishing the Bioequivalence Safe Space for Immediate-Release Oral Dosage Forms using Physiologically Based Biopharmaceutics Modeling (PBBM): Case Studies. Heimbach T; Kesisoglou F; Novakovic J; Tistaert C; Mueller-Zsigmondy M; Kollipara S; Ahmed T; Mitra A; Suarez-Sharp S J Pharm Sci; 2021 Dec; 110(12):3896-3906. PubMed ID: 34551349 [TBL] [Abstract][Full Text] [Related]
32. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib. Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875 [TBL] [Abstract][Full Text] [Related]
33. A New Level A Type IVIVC for the Rational Design of Clinical Trials Toward Regulatory Approval of Generic Polymeric Long-Acting Injectables. Somayaji MR; Das D; Przekwas A Clin Pharmacokinet; 2016 Oct; 55(10):1179-1190. PubMed ID: 27349905 [TBL] [Abstract][Full Text] [Related]
34. Prediction of in vivo drug performance using in vitro dissolution coupled with STELLA: a study with selected drug products. Chakraborty S; Yadav L; Aggarwal D Drug Dev Ind Pharm; 2015; 41(10):1667-73. PubMed ID: 25494535 [TBL] [Abstract][Full Text] [Related]
35. In vitro biorelevant models for evaluating modified release mesalamine products to forecast the effect of formulation and meal intake on drug release. Andreas CJ; Chen YC; Markopoulos C; Reppas C; Dressman J Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):39-50. PubMed ID: 26391972 [TBL] [Abstract][Full Text] [Related]
36. Nanomedicines accessible in the market for clinical interventions. Gadekar V; Borade Y; Kannaujia S; Rajpoot K; Anup N; Tambe V; Kalia K; Tekade RK J Control Release; 2021 Feb; 330():372-397. PubMed ID: 33370576 [TBL] [Abstract][Full Text] [Related]
38. Power of the Dissolution Test in Distinguishing a Change in Dosage Form Critical Quality Attributes. Gray VA AAPS PharmSciTech; 2018 Nov; 19(8):3328-3332. PubMed ID: 30350251 [TBL] [Abstract][Full Text] [Related]
39. Data Analytics Approach for Rational Design of Nanomedicines with Programmable Drug Release. Mullis AS; Broderick SR; Binnebose AM; Peroutka-Bigus N; Bellaire BH; Rajan K; Narasimhan B Mol Pharm; 2019 May; 16(5):1917-1928. PubMed ID: 30973741 [TBL] [Abstract][Full Text] [Related]
40. Interpretation and optimization of the dissolution specifications for a modified release product with an in vivo-in vitro correlation (IVIVC). Hayes S; Dunne A; Smart T; Davis J J Pharm Sci; 2004 Mar; 93(3):571-81. PubMed ID: 14762896 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]